Signal Pharma to develop new treatments for major diseases

Published: 12-Mar-2012
Research & Development Cardiovascular Pharmaceutical

Aberdeen University spin out will focus on breast cancer, heart failure, diabetes and chronic pain

The University of Aberdeen is working with Scottish entrepreneur Dr Derek Douglas CBE to spin out a company that will develop new drugs to treat breast cancer, heart failure, diabetes and chronic pain.

Signal Pharma will be the first company to be spun out from the University’s Kosterlitz Centre for Therapeutics, which is focused on translating biological innovation into new ways of treating, diagnosing and understanding diseases.

The founders of the company are pharmacology expert Professor Ruth Ross and Dr Iain Greig, a medicinal chemist who helped found another University spin out that is developing drugs to treat rheumatoid arthritis. They have joined forces with cardiologist Professor Michael Frenneaux, and molecular imaging expert Professor Matteo Zanda. Dr Derek Douglas, chairman and ceo of Adam Smith Ltd is providing financial and business acumen, while Dr Michael Wyllie, founder and director Global Pharma Consulting, will provide drug development expertise.

Sigma Pharma will develop a portfolio of four drug discovery projects based on new pathways and targets identified by the University of Aberdeen scientists.

The firm is seeking to raise £1.5m to develop these projects over a period of three years.

Prof Ross, who is also director of the University’s Kosterlitz Centre, said: ‘The creation of Signal Pharma is a great opportunity to generate both medical and economic benefits based on the world class biomedical research of discoveries of the University of Aberdeen.’

Dr Greig added: ‘It is particularly satisfying to see ideas that we have worked on for many years reaching the next stage of the development process, which we hope will eventually lead to new drugs that give real benefits to the patients, saving lives and reducing suffering.’

See more

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Read more
Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes

Trending Articles

  1. Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling New X and S Series models offer high performance with reduced environmental impact
  2. Servier and University College London partner to advance research in rare genetic epileptic disorders Servier will collaborate with UCL to evaluate antisense oligonucleotide candidates in cutting-edge brain assembloid models, aiming to accelerate therapeutic advances for patients with developmental and epileptic encephalopathy (DEE)
  3. Ardena strengthens executive leadership with key quality and IT appointments Appointments reflect focus on quality, compliance, and digital integration across global network
  4. AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
  5. Experts uncover how bacteria modify themselves to outsmart antibiotics Scientists from the University of Nottingham are part of an international collaboration which has taken a step closer to understanding why bacteria can become resistant to antibiotics

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes
Research & Development

Aberdeen University wins £5.1m grant to tackle fungal infections

New strategies needed to combat life-threatening invasive fungal infections
Research & Development

Drug discovery centre to open in Aberdeen

Kosterlitz Centre for Therapeutics will take ideas from bench to bedside
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Research & Development

Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Research & Development

Lilly’s Jaypirca outperforms Imbruvica in landmark Phase III CLL trial, showing higher response rates and strong PFS trend

Pirtobrutinib met its primary endpoint and delivered higher overall response rates than ibrutinib in the BRUIN CLL-314 study, with early progression-free survival data also favouring Lilly’s next-generation BTK inhibitor
Subscribe now